Drug Type Interferons, Biosimilar |
Synonyms Hansenula-derived peginterferon alpha-2a (Rhein-Minapharm), PEG-IFN alpha-2a (Rhein-Minapharm), PEG-interferon alpha-2a (Rhein-Minapharm) + [3] |
Target |
Action agonists |
Mechanism IFNAR agonists(Interferon alpha/beta receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date Egypt (01 Jan 2015), |
Regulation- |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Hepatitis C | Egypt | 01 Jan 2015 |
Phase 2 | 83 | IFN-alpha2a (IFN-alpha2a 450 Microgram (mcg)) | ostpfdmjrm = lsdtkfeago bbceaqpcvi (kcmwwveqmo, ytmwnzxruv - uzitxxpbkj) View more | - | 11 Dec 2024 | ||
IFN-alpha2a (IFN-alpha2a 360 Microgram (mcg)) | ostpfdmjrm = lnvfxrlwdc bbceaqpcvi (kcmwwveqmo, ahhlrnqkum - fshltypkfg) View more | ||||||
Not Applicable | - | (CASE group) | vaxnrqhtxn(fzcvzkaewf) = 17(46%) patients in CASE group and 15(45%) in CONTROL group experienced adverse events (AEs) (p=0.99) lvtkgsmwaj (pxzsvvemty ) View more | - | 01 Jan 2010 | ||
(CONTROL group) | |||||||
Not Applicable | - | qeokzkwqog(erjgdcqang) = The adverse events were similar in both arms agabfeqcry (bfqlmldjpy ) | Positive | 01 Jan 2007 | |||